Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom
<p><strong>Aims:</strong><br /> Statins are widely used to prevent cardiovascular events, but little is known about the impact of different risk factors for statin-related myopathy or their relevance to reports of other types of muscle symptom.</p><br /> <p>...
Päätekijät: | Hopewell, JC, Offer, A, Haynes, R, Bowman, L, Li, J, Chen, F, Bulbulia, R, Lathrop, M, Baigent, C, Landray, MJ, Collins, R, Armitage, J, Parish, S |
---|---|
Muut tekijät: | HPS Collaborative Group |
Aineistotyyppi: | Journal article |
Kieli: | English |
Julkaistu: |
Oxford University Press
2020
|
Samankaltaisia teoksia
-
Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.
Tekijä: Hopewell, J, et al.
Julkaistu: (2013) -
Environmental and genetic risk factors for myopathy in Chinese participants from HPS2-THRIVE
Tekijä: Hopewell, J, et al.
Julkaistu: (2012) -
Regarding "Does simvastatin save lives; If so, when and in whom?" - Reply
Tekijä: Bulbulia, R, et al.
Julkaistu: (2008) -
Safety of long-term simvastatin discontinuation Reply
Tekijä: Bulbulia, R, et al.
Julkaistu: (2012) -
Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.
Tekijä: Armitage, J, et al.
Julkaistu: (2010)